{"component": "clause", "props": {"groups": [{"snippet": "The primary endpoints are occurrence of all adverse events including but not limited to: \u00b7 all MIs \u00b7 cardiovascular hospitalization \u00b7 serious ventricular arrhythmias sustained \u00b7 VT (symptomatic or sustained VT [duration longer than 30 seconds or 100 beats, or associated with hemodynamic collapse] \u00b7 VF \u00b7 symptomatic bradycardia, pauses of longer than 3.0 seconds, complete atrioventricular block, Mobitz II atrioventricular block \u00b7 symptomatic heart failure (NYHA criteria + physical examination OR hospitalization due to heart failure) \u00b7 renal failure \u00b7 stroke \u00b7 death Secondary Endpoints include the parameters: \u00b7 change from baseline in LV dimensions (end-systolic volume index, end-diastolic volume index, left ventricular mass) \u00b7 change from baseline in regional (infarct related) and global wall motion score \u00b7 change from baseline in ejection fraction \u00b7 cardiac rupture \u00b7 NT-proBNP", "size": 7, "snippet_links": [{"key": "primary-endpoints", "type": "clause", "offset": [4, 21]}, {"key": "adverse-events", "type": "clause", "offset": [44, 58]}, {"key": "not-limited", "type": "clause", "offset": [73, 84]}, {"key": "associated-with", "type": "definition", "offset": [260, 275]}, {"key": "heart-failure", "type": "clause", "offset": [445, 458]}, {"key": "physical-examination", "type": "definition", "offset": [476, 496]}, {"key": "renal-failure", "type": "definition", "offset": [540, 553]}, {"key": "secondary-endpoints", "type": "clause", "offset": [571, 590]}], "samples": [{"hash": "aqqfj3FR3dp", "uri": "/contracts/aqqfj3FR3dp#endpoints", "label": "License and Commercialization Agreement (Bellerophon Therapeutics, Inc.)", "score": 26.2429847717, "published": true}, {"hash": "eqgtMpj78Xc", "uri": "/contracts/eqgtMpj78Xc#endpoints", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 26.032169342, "published": true}, {"hash": "117iSGFYTmU", "uri": "/contracts/117iSGFYTmU#endpoints", "label": "License and Commercialization Agreement (Bellerophon Therapeutics LLC)", "score": 25.3641338348, "published": true}], "hash": "b6614ea2ec1d12d8098e71be060e49ca", "id": 1}, {"snippet": "The impact of MS and CRP on vascular phenotype in DM2 was assessed using sonographic vascular parameters, IMT, and flow mediated dilatation (FMD), as well as the following en- dothelium-related and hemostatic factors: fibrinogen, s-thrombomodulin (sTM), tissue type plasminogen-activator (tPA), plasminogen-activator inhibitor-1 (PAI-1), sVCAM, sE-selectin, and von Willebrand factor (VWF).", "size": 3, "snippet_links": [], "samples": [{"hash": "lxZNDKVUKqY", "uri": "/contracts/lxZNDKVUKqY#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}, {"hash": "lHXpfmBJwsh", "uri": "/contracts/lHXpfmBJwsh#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}, {"hash": "7vWqpqmKvz2", "uri": "/contracts/7vWqpqmKvz2#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}], "hash": "479b814d3da72f58d378f3fc6896702d", "id": 2}, {"snippet": "Genesys users can only access the Cloud Services Environment from Genesys- managed endpoints. Genesys-managed endpoints have hard drive encryption enabled;", "size": 3, "snippet_links": [{"key": "cloud-services-environment", "type": "definition", "offset": [34, 60]}, {"key": "managed-endpoints", "type": "definition", "offset": [75, 92]}, {"key": "hard-drive", "type": "definition", "offset": [125, 135]}], "samples": [{"hash": "helxJ1KnMXs", "uri": "/contracts/helxJ1KnMXs#endpoints", "label": "Data Processing Addendum", "score": 36.429233551, "published": true}, {"hash": "dTYBy92Zwz5", "uri": "/contracts/dTYBy92Zwz5#endpoints", "label": "Data Processing Addendum", "score": 36.2168579102, "published": true}, {"hash": "lAbL1Be4prK", "uri": "/contracts/lAbL1Be4prK#endpoints", "label": "Data Processing Addendum", "score": 36.1937446594, "published": true}], "hash": "50c264d9eac2d45fe2bcc2b7a1331132", "id": 3}, {"snippet": "The endpoints of this study were differences in inflammatory markers (serum C-reactive protein (CRP) and fibrinogen levels), endothelial function (as estimated using measure- ment of flow mediated dilation (FMD)) and carotid intima-media thickness (CIMT) as a", "size": 3, "snippet_links": [], "samples": [{"hash": "lxZNDKVUKqY", "uri": "/contracts/lxZNDKVUKqY#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}, {"hash": "lHXpfmBJwsh", "uri": "/contracts/lHXpfmBJwsh#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}, {"hash": "7vWqpqmKvz2", "uri": "/contracts/7vWqpqmKvz2#endpoints", "label": "Doctoral Thesis", "score": 18.0, "published": true}], "hash": "6a4b6b4a0b93a4c6f0708ce7f76f78d3", "id": 4}, {"snippet": "(i) Avaya shall use its commercially reasonable efforts to cause (x) the Avaya Endpoints existing as of the Effective Date to be, as soon as reasonably practicable following the Effective Date, and (y) future Avaya Endpoints to be, at all times prior to such Avaya Endpoints being Sold, in each case, compatible with ACO and the other RingCentral Services, and (ii) RingCentral shall use its commercially reasonable efforts to cause (x) the RingCentral Services existing as of the Effective Date to be, as soon as reasonably practicable following the Effective Date, and (y) future RingCentral Services to be, at all times prior to the RingCentral Services being Sold, in each case, compatible with the Avaya Endpoints. To the extent an Avaya Endpoint and the RingCentral Services are so compatible, RingCentral shall offer such Avaya Endpoint as part of its and its Subsidiaries\u2019 product catalogs at least as prominently and positively in the ordinary course of business, in all material respects, as any other RingCentral Offering that is designed to provide substantially similar functionality (taken as a whole) and is then\u2011currently Marketed in such product catalogs in the ordinary course of business. Each Party acknowledges that the other Party\u2019s performance of its obligations under this Section 2.3(e) depends on such Party\u2019s compliance with this Section 2.3(e) and timely, accurate and effective delivery of all information to make the Avaya Endpoints compatible with ACO, and the other RingCentral Services compatible with the Avaya Endpoints, including such information, cooperation, and assistance reasonably required by either Party. Each Party further acknowledges and agrees that its failure to satisfy any such responsibilities may prevent or delay the other Party\u2019s performance of its obligations under this Section 2.3(e). The Parties agree to work together in good faith to develop a mutually agreed process pursuant to which Avaya will sell to RingCentral certain Avaya Endpoints on commercially favorable terms.", "size": 2, "snippet_links": [{"key": "commercially-reasonable-efforts", "type": "definition", "offset": [24, 55]}, {"key": "as-of-the-effective-date", "type": "clause", "offset": [98, 122]}, {"key": "following-the-effective-date", "type": "clause", "offset": [164, 192]}, {"key": "at-all-times", "type": "definition", "offset": [232, 244]}, {"key": "each-case", "type": "definition", "offset": [290, 299]}, {"key": "ringcentral-services", "type": "definition", "offset": [335, 355]}, {"key": "services-to-be", "type": "clause", "offset": [594, 608]}, {"key": "prior-to-the", "type": "clause", "offset": [623, 635]}, {"key": "to-the-extent", "type": "clause", "offset": [720, 733]}, {"key": "product-catalogs", "type": "clause", "offset": [881, 897]}, {"key": "in-the-ordinary-course-of-business", "type": "definition", "offset": [937, 971]}, {"key": "in-all-material-respects", "type": "definition", "offset": [973, 997]}, {"key": "to-provide", "type": "definition", "offset": [1050, 1060]}, {"key": "substantially-similar", "type": "definition", "offset": [1061, 1082]}, {"key": "taken-as-a-whole", "type": "clause", "offset": [1098, 1114]}, {"key": "each-party", "type": "clause", "offset": [1208, 1218]}, {"key": "other-party", "type": "clause", "offset": [1241, 1252]}, {"key": "such-party", "type": "clause", "offset": [1323, 1333]}, {"key": "compliance-with-this-section", "type": "clause", "offset": [1336, 1364]}, {"key": "delivery-of", "type": "clause", "offset": [1407, 1418]}, {"key": "all-information", "type": "clause", "offset": [1419, 1434]}, {"key": "such-information", "type": "definition", "offset": [1566, 1582]}, {"key": "by-either-party", "type": "clause", "offset": [1632, 1647]}, {"key": "failure-to-satisfy", "type": "clause", "offset": [1701, 1719]}, {"key": "agree-to", "type": "clause", "offset": [1855, 1863]}, {"key": "in-good-faith", "type": "definition", "offset": [1878, 1891]}, {"key": "to-develop", "type": "definition", "offset": [1892, 1902]}, {"key": "agreed-process", "type": "definition", "offset": [1914, 1928]}, {"key": "pursuant-to", "type": "definition", "offset": [1929, 1940]}, {"key": "favorable-terms", "type": "definition", "offset": [2018, 2033]}], "samples": [{"hash": "8kYN9dnUtwc", "uri": "/contracts/8kYN9dnUtwc#endpoints", "label": "Framework Agreement (RingCentral, Inc.)", "score": 31.1519508362, "published": true}, {"hash": "aMURUw9LsbI", "uri": "/contracts/aMURUw9LsbI#endpoints", "label": "Framework Agreement (Avaya Holdings Corp.)", "score": 31.1081447601, "published": true}], "hash": "be627945bfdfcc2078307a2230bda803", "id": 5}, {"snippet": "The incidence and course (timing, location of pain and duration) of myalgia after conditioning were the primary endpoints. Secondary endpoint was pain severity according to the WHO pain relief ladder. Other variables noted above were collected to evaluate potential predisposing factors. Descriptive statistics, such as median and frequency, were used to summarize baseline characteristics and outcomes. Odds ratios (OR) were estimated by means of logistic regression to examine the association between conditioning regimen (TREO-based vs. BU-based) and myalgia and adjusted for possible confounding (hemoglobinopathies versus other indications). In the TREO cohort, univariable and multivariable logistic regression was performed to assess whether baseline- or transplant characteristics (age, underlying disease, conditioning regimen, treosulfan exposure) were prognostic for the development of myalgia. All P-values were 2-tailed and considered significant when P<0.05. Statistical 5 analyses were performed using R version 3.6.1 and RStudio version 1.2.5019.", "size": 2, "snippet_links": [{"key": "location-of", "type": "definition", "offset": [34, 45]}, {"key": "and-duration", "type": "clause", "offset": [51, 63]}, {"key": "primary-endpoints", "type": "clause", "offset": [104, 121]}, {"key": "according-to", "type": "definition", "offset": [160, 172]}, {"key": "other-variables", "type": "clause", "offset": [201, 216]}, {"key": "descriptive-statistics", "type": "clause", "offset": [288, 310]}, {"key": "baseline-characteristics", "type": "clause", "offset": [365, 389]}, {"key": "logistic-regression", "type": "clause", "offset": [448, 467]}, {"key": "the-association", "type": "clause", "offset": [479, 494]}, {"key": "other-indications", "type": "definition", "offset": [627, 644]}, {"key": "development-of", "type": "clause", "offset": [882, 896]}, {"key": "all-p", "type": "clause", "offset": [906, 911]}], "samples": [{"hash": "94rDVS0hSxW", "uri": "/contracts/94rDVS0hSxW#endpoints", "label": "Pharmacokinetics and Dynamics Study", "score": 25.3723468781, "published": true}, {"hash": "1VrrVVNB47S", "uri": "/contracts/1VrrVVNB47S#endpoints", "label": "Doctoral Thesis", "score": 25.3723468781, "published": true}], "hash": "ec34d654de43e1ca5a3ffaa1749d7a09", "id": 6}, {"snippet": "Except as otherwise expressly stated to the contrary in the applicable Cloud Offer Definition or Avaya\u2019s quotation, Avaya is not responsible for the provision of any end points or similar devices necessary to deploy Cloud Services for any Reseller or Cloud End User, including personal end points, personal computers, mobile devices and telepresence or room systems.", "size": 2, "snippet_links": [{"key": "the-applicable", "type": "clause", "offset": [56, 70]}, {"key": "responsible-for", "type": "clause", "offset": [129, 144]}, {"key": "provision-of", "type": "clause", "offset": [149, 161]}, {"key": "services-for", "type": "clause", "offset": [222, 234]}, {"key": "end-user", "type": "definition", "offset": [257, 265]}, {"key": "personal-computers", "type": "clause", "offset": [298, 316]}, {"key": "mobile-devices", "type": "clause", "offset": [318, 332]}], "samples": [{"hash": "eywlPFaojER", "uri": "/contracts/eywlPFaojER#endpoints", "label": "Distributor Agreement", "score": 30.3408622742, "published": true}, {"hash": "gLt8dUYZptN", "uri": "/contracts/gLt8dUYZptN#endpoints", "label": "Distributor Agreement (Scansource, Inc.)", "score": 28.3511295319, "published": true}], "hash": "cdf01b117f3ebd321d6efb80e0aecae0", "id": 7}, {"snippet": "Except as otherwise expressly stated to the contrary in the applicable Cloud Offer Definition or any quotation, Distributor is not responsible for the provision of any end points or similar devices necessary to deploy Cloud Services for any Cloud End User, including personal end points, personal computers, mobile devices and telepresence or room systems.", "size": 2, "snippet_links": [{"key": "the-applicable", "type": "clause", "offset": [56, 70]}, {"key": "responsible-for", "type": "clause", "offset": [131, 146]}, {"key": "provision-of", "type": "clause", "offset": [151, 163]}, {"key": "services-for", "type": "clause", "offset": [224, 236]}, {"key": "end-user", "type": "definition", "offset": [247, 255]}, {"key": "personal-computers", "type": "clause", "offset": [288, 306]}, {"key": "mobile-devices", "type": "clause", "offset": [308, 322]}], "samples": [{"hash": "4DwU3IXVjKv", "uri": "/contracts/4DwU3IXVjKv#endpoints", "label": "Cloud Services Reseller Addendum", "score": 27.5094604492, "published": true}, {"hash": "5gJdmdieizd", "uri": "/contracts/5gJdmdieizd#endpoints", "label": "Cloud Services Reseller Addendum", "score": 24.2553043365, "published": true}], "hash": "57947ecae4311e14ef5e874bdf19aa19", "id": 8}, {"snippet": "5.5.1 Primary Efficacy Endpoint 90-day global disability assessed with the modified \u2587\u2587\u2587\u2587\u2587\u2587 Scale", "size": 1, "snippet_links": [{"key": "primary-efficacy-endpoint", "type": "clause", "offset": [6, 31]}], "samples": [{"hash": "7S4JP98bdXW", "uri": "/contracts/7S4JP98bdXW#endpoints", "label": "Investigator Agreement", "score": 33.8201131479, "published": true}], "hash": "44c6981cb7319e4a255748fc2ec88e26", "id": 9}, {"snippet": "If the clinical endpoints for a Phase 1A/1B Study are not met, the Parties shall discuss in good faith potential amendments to the Research Plan, Research Budget and Phase 1A/1B Plan to accommodate an additional Phase 1A/1B Study; such amendments to be consistent with the Research Principles and/or Development Principles, as applicable. In no event may Curis conduct a Phase 2 Trial of a Product during the Option Period.", "size": 1, "snippet_links": [{"key": "a-phase", "type": "definition", "offset": [30, 37]}, {"key": "not-met", "type": "definition", "offset": [54, 61]}, {"key": "the-parties-shall", "type": "clause", "offset": [63, 80]}, {"key": "in-good-faith", "type": "definition", "offset": [89, 102]}, {"key": "amendments-to-the-research-plan", "type": "clause", "offset": [113, 144]}, {"key": "research-budget", "type": "definition", "offset": [146, 161]}, {"key": "additional-phase", "type": "definition", "offset": [201, 217]}, {"key": "consistent-with-the", "type": "clause", "offset": [253, 272]}, {"key": "research-principles", "type": "definition", "offset": [273, 292]}, {"key": "development-principles", "type": "clause", "offset": [300, 322]}, {"key": "in-no-event", "type": "clause", "offset": [339, 350]}, {"key": "phase-2-trial", "type": "definition", "offset": [371, 384]}, {"key": "during-the-option-period", "type": "clause", "offset": [398, 422]}], "samples": [{"hash": "ldamEC5xgC2", "uri": "/contracts/ldamEC5xgC2#endpoints", "label": "Option and License Agreement (Curis Inc)", "score": 31.2121829987, "published": true}], "hash": "e007b2b1dc0839f5961375580222c3ea", "id": 10}], "next_curs": "ClISTGoVc35sYXdpbnNpZGVyY29udHJhY3Rzci4LEhZDbGF1c2VTbmlwcGV0R3JvdXBfdjU2IhJlbmRwb2ludHMjMDAwMDAwMGEMogECZW4YACAA", "clause": {"title": "Endpoints", "size": 40, "children": [["primary-endpoints", "Primary Endpoints"], ["secondary-endpoints", "Secondary Endpoints"], ["", ""], ["guidelines", "Guidelines"], ["patent-and-patent-cross-license", "Patent and Patent Cross License"]], "parents": [["miscellaneous-provisions", "Miscellaneous Provisions"], ["execution-in-counterparts-facsimile-signatures", "Execution in Counterparts; Facsimile Signatures"], ["concomitant-medication", "Concomitant medication"], ["pregnancy", "Pregnancy"], ["security-incident-response", "Security Incident Response"]], "id": "endpoints", "related": [["evaluation-criteria", "Evaluation Criteria", "Evaluation Criteria"], ["study", "Study", "Study"], ["study-population", "Study Population", "Study Population"], ["population", "Population", "Population"], ["target-population", "Target Population", "Target Population"]], "related_snippets": [], "updated": "2025-07-18T05:45:24+00:00"}, "json": true, "cursor": ""}}